ArticleClinical and experimental immunology2009
Induction of autoimmune cholangitis in non-obese diabetic (NOD).1101 mice following a chemical xenobiotic immunization.
Article in Clinical and experimental immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 82 citations in OpenAlex.
- Liver immunity, autoimmunity, and inborn errors of immunity.World journal of hepatology · 2023Review
- Linking Human Betaretrovirus with Autoimmunity and Liver Disease in Patients with Primary Biliary Cholangitis.Viruses · 2022Review
- Animal Models of Autoimmune Liver Diseases: a Comprehensive Review.Clinical reviews in allergy & immunology · 2020Review
- Examining pathogenic concepts of autoimmune hepatitis for cues to future investigations and interventions.World journal of gastroenterology · 2019Review
- Industrial, Biocide, and Cosmetic Chemical Inducers of Cholestasis.Chemical research in toxicology · 2019Article
- Preclinical insights into cholangiopathies: disease modeling and emerging therapeutic targets.Expert opinion on therapeutic targets · 2019Review
- Identification of a xenobiotic as a potential environmental trigger in primary biliary cholangitis.Journal of hepatology · 2018Article
- Epigenetics in the Primary Biliary Cholangitis and Primary Sclerosing Cholangitis.Seminars in liver disease · 2017Article
- The induction of autoimmune hepatitis in the human leucocyte antigen-DR4 non-obese diabetic mice autoimmune hepatitis mouse model.Clinical and experimental immunology · 2016Article
- Endogenous interleukin-22 protects against inflammatory bowel disease but not autoimmune cholangitis in dominant negative form of transforming growth factor beta receptor type II mice.Clinical and experimental immunology · 2016Article
- A contemporary perspective on the molecular characteristics of mitochondrial autoantigens and diagnosis in primary biliary cholangitis.Expert review of molecular diagnostics · 2016Review
- Adaptive immunity in the liver.Cellular & molecular immunology · 2016Review
- Xenobiotics and loss of tolerance in primary biliary cholangitis.World journal of gastroenterology · 2016Review
- The immunogenetics of primary biliary cirrhosis: A comprehensive review.Journal of autoimmunity · 2015Review
- Genome-Wide Association Studies in Primary Biliary Cirrhosis.Seminars in liver disease · 2015Review
- Primary biliary cirrhosis: From bench to bedside.World journal of gastrointestinal pharmacology and therapeutics · 2015Review
- Animal models of primary biliary cirrhosis.Clinical reviews in allergy & immunology · 2015Review
- Animal models in primary biliary cirrhosis and primary sclerosing cholangitis.Clinical reviews in allergy & immunology · 2015Review
- Environmental factors in primary biliary cirrhosis.Seminars in liver disease · 2014Review
- Primary biliary cirrhosis: Family, genes, and bugs.Clinical liver disease · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 7 institutions in 4 countries.
Funding
Abstract
Our laboratory has suggested that loss of tolerance to pyruvate dehydrogenase (PDC-E2) leads to an anti-mitochondrial antibody response and autoimmune cholangitis, similar to human primary biliary cirrhosis (PBC). We have suggested that this loss of tolerance can be induced either via chemical xenobiotic immunization or exposure to select bacteria. Our work has also highlighted the importance of genetic susceptibility. Using the non-obese diabetic (NOD) congenic strain 1101 (hereafter referred to as NOD.1101 mice), which has chromosome 3 regions from B6 introgressed onto a NOD background, we exposed animals to 2-octynoic acid (2OA) coupled to bovine serum albumin (BSA). 2OA has been demonstrated previously by a quantitative structural activity relationship to react as well as or better than lipoic acid to anti-mitochondrial antibodies. We demonstrate herein that NOD.1101 mice immunized with 2OA-BSA, but not with BSA alone, develop high titre anti-mitochondrial antibodies and histological features, including portal infiltrates enriched in CD8(+) cells and liver granulomas, similar to human PBC. We believe this model will allow the rigorous dissection of early immunogenetic cause of biliary damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.